Present and future of biologic drugs in primary Sjögren’s syndrome

Expert Opinion on Biological Therapy

Volumn 17, Issue 1, 2017, Pages 63-75

  Sambataro, Domenico ^a,b   Sambataro, Gianluca ^b   Dal Bosco, Ylenia ^a   Polosa, Riccardo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Outpatient Clinic of Rheumatology accredited to National Health System   (Italy)

Author keywords

Biological therapy; physiopathology; review; Sj gren s syndrome

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; BIOLOGICAL PRODUCT; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; BIOLOGICAL FACTOR; IL17A PROTEIN, HUMAN;

B LYMPHOCYTE; BIOLOGICAL THERAPY; HUMAN; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIMARY SJOEGREN SYNDROME; REVIEW; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; T LYMPHOCYTE; ANIMAL; CLINICAL TRIAL (TOPIC); FORECASTING; IMMUNOLOGY; PATHOLOGY; PROCEDURES; SJOGREN'S SYNDROME; TRENDS;

ANIMALS; B-LYMPHOCYTES; BIOLOGICAL FACTORS; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; CLINICAL TRIALS AS TOPIC; FORECASTING; HUMANS; INTERLEUKIN-17; SJOGREN'S SYNDROME;

EID: 85002523494     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2017.1235698     Document Type: Review

References (125)

1. Mavragani CP, Moutsopoulos HM., Sjögren syndrome. CMAJ. 2014;186(15):E579–E586. DOI:10.1503/cmaj.122037
2. Qin B, Wang J, Yang Z, et al. Epidemiology of primary Sjögren’s syndrome:a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(11):1983–1989. DOI:10.1136/annrheumdis-2014-205375
3. Bayetto K, Logan RM. Sjogren’s syndrome:a review of aetiology, pathogenesis, diagnosis and management. Aust Dent J. 2010;55(1):39–47. DOI:10.1111/j.1834-7819.2010.01197.x
4. Roescher N, Tak PP, Illei GG. Cytokines in Sjögren syndrome. Oral Dis. 2009;15(8):519–526. DOI:10.1111/j.1601-0825.2009.01582.x
5. Keystone EC. The utility of tumour necrosis factor blockade in orphan diseases. Ann Rheum Dis. 2004;63(suppl 2):ii79–ii83. DOI:10.1136/ard.2004.028498
6. Sisto M, D’amore M, Caprio S, et al. Tumor necrosis factor inhibitors block apoptosis of human epithelial cells of salivary glands. Ann NY Acad Sci. 2009;1171:407–414. DOI:10.1111/j.1749-6632.2009.04688.x
7. Sisto M, Lisi S, Lofrumento DD, et al. TNF blocker drugs modulate human TNF-α-converting enzyme pro-domain shedding induced by autoantibodies. Immunobiology. 2010;215(11):874–883. DOI:10.1016/j.imbio.2009.11.005
8. Aoka K, Azuma M. Targeting TNF-α suppresses the production of MMP-9 in human salivary gland. Arch Oral Biol. 2013;58(12):1761–1768. DOI:10.1016/j.archoralbio.2013.09.004
9. Zandbelt MM, De Wilde P, Van Damme P, et al. Etanercept in the treatment of patients with primary Sjögren syndrome:a pilot study. J Rheumatol. 2004;31(1):96–101.
10. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjögren syndrome:a twelve-week randomized, doble-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50(7):2240–2245. DOI:10.1002/art.20299
11. Mariette X, Ravaud P, Steinfel S, et al. Inefficacy of infliximab in primary Sjögren’s syndrome:results of the randomized, controlled trial of remicade in primary Sjögren’s syndrome (TRIPSS). Arthritis Rheum. 2004;50(4):1270–1276. DOI:10.1002/art.20146
12. Steinfeld SD, Demols P, Salmon I, et al. Notice of retraction of two articles (“infliximab in patients with primary Sjogren’s syndrome:a pilot study” and “infliximab in patients with primary Sjogren’s syndrome:one year followup”). Arthritis Rheum. 2013;65(3):814. DOI:10.1002/art.37942
13. Mavragan CP, Niewold TB, Moutsopoulos NM, et al. Augmented interferon-alpha patway activation in patients with Sjögren’s syndrome trated with etanercept. Arthritis Rheum. 2007;56(1):3995–4004. DOI:10.1002/art.23062
14. Moutsopoulos NM, Katsifis GE, Angelov N, et al. Lack of efficacy of etanercept in Sjögren’s syndrome correlates with failed suppression of tumor necrosis factor alpha and systemic immune activation. Ann Rheum Dis. 2008;67(10):1437–1443. DOI:10.1136/ard.2007.077891
15. Youinou P, Devauchelle-Pensec V, Pers JO. Significance of B cells and B cell clonality in Sjogren’s syndrome. Arthritis Rheum. 2010;62(9):2605–2610. DOI:10.1002/art.27564
16. Shen L, Suresh L, Lindemann M, et al. Novel autoantibodies in Sjogren’s syndrome. Clin Immunol. 2012;145(3):251–255. DOI:10.1016/j.clim.2012.09.013
17. Tzioufas AG, Manoussakis MN, Costello R, et al. Cryoglobulinemia in autoimmune rheumatic diseases. Evidence of circulating monoclonal cryoglobulins in patient with primary Sjogrens’s syndrome. Arthritis Rheum. 1986;29:1098–1104.
18. Sugai S, Konda S, Shoraski Y, et al. Non-IgM monoclonal gammopathy in patients with Sjogrens’s syndrome. Am J Med. 1980;68:861–866.
19. Royer B, Cazals-Hatem D, Sibilia J, et al. Lymphomas in patients with Sjogren’s syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood. 1997;90(2):766–775.
20. Mackay F, Silveira PA, Brink R. B cells and the BAFF/APRIL axis:fast-forward on autoimmunity and signaling. Curr Opin Immunol. 2007;19:327–336. DOI:10.1016/j.coi.2007.04.008
21. Mackay F, Browning J. BAFF:a fundamental survival factor for B cells. Nature Rev Immunol. 2002;2(7):465–475. DOI:10.1038/nri844
22. Mackay F, Leung H. The role of the BAFF/APRIL system of T cell function. Semin Immunol. 2006;18(5):284–289. DOI:10.1016/j.smim.2006.04.005
23. He B, Chadburn A, Jou E, et al. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol. 2004;172(5):3268–3279.
24. D’Arbonneau F, Pers JO, Devauchelle-Pensec V, et al. BAFF-induced changes in B cell receptor-containing lipid rafts in Sjogren’s syndrome. Arthritis Rheum. 2006;54:115–126. DOI:10.1002/art.21478
25. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BlyS overexpression and altered B cell differentiation with Sjogren’s syndrome. J Clin Invest. 2002;109(1):59–68. DOI:10.1172/JCI14121
26. Vadacca M, Margiotta D, Sambataro D, et al. BAFF/APRIL pathway in Sjogren syndrome and systemic lupus erythematosus:relationship with chronic inflammation and disease activity. Reumatismo. 2010;62(4):259–265.•• This review summarizes the role of BAFF/APRIL in Sjögren syndrome.
27. Quartuccio L, Salvin S, Fabris M, et al. BLyS upregulation in Sjogren’s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford). 2013;52(2):276–281. DOI:10.1093/rheumatology/kes180
28. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren syndrome with rituximab:results of a randomized, double blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67(11):1541–1544. DOI:10.1136/ard.2007.083865• This research article discusses about the efficacy of Rituximab for the treatment of Sjögren syndrome in a clinical trial.
29. Pijpe J, Meijer JM, Bootsma H, et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of Rituximab treatment in Sjogren’s syndrome. Arthritis Rheum. 2009;60(11):3251–3256. DOI:10.1002/art.24903
30. Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of Rituximab in systemic manifestations of primary Sjogren’s syndrome:results in 78 patients of the Autoimmune and Rituximab registry. Ann Rheum Dis. 2013;72(6):1026–1031. DOI:10.1136/annrheumdis-2012-202293
31. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome:a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(4):960–968. DOI:10.1002/art.27314
32. Meiners PM, Arends S, Meijer JM, et al. Efficacy of retreatment with rituximab in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol. 2015;33(3):443–444.
33. St Clair EW, Levesque MC, Prak ET, et al. Rituximab therapy for primary Sjogren’s syndrome:an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 2013;65(4):1097–1106. DOI:10.1002/art.37850
34. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjogren syndrome with rituximab:a randomized trial. Ann Intern Med. 2014;160(4):233–242. DOI:10.7326/M13-1085.• This research article concerns another clinical trial about the efficacy of Rituximab for the treatment of Sjögren syndrome
35. Bowman S, Everett C, Bombardieri M, et al. Preliminary results of a double-blind randomized trial of Rituximab anti-B-cell therapy in patients with primary Sjogren’s syndrome [abstract]. Arthritis Rheumatol. 2015;61(10). Available from:http://acrabstracts.org/abstract/preliminary-results-of-a-double-blind-randomised-trial-of-rituximab-anti-b-cell-therapy-in-patients-with-primary-sjogrens-syndrome/
36. Cornec D, Devauchelle-Pensec V, Mariette X, et al. Development of the Sjögren’s syndrome responder index, a data-driven composite endpoint for assessing treatment efficacy. Rheumatology (Oxford). 2015;54(9):1699–1708. DOI:10.1093/rheumatology/kev114
37. Moeman RV, Arends S, Meiners PM, et al. EULAR Sjogren’s Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomized controlled trial. Ann Rheum Dis. 2014;73(2):472–474. DOI:10.1136/annrheumdis-2013-203736
38. Devauchelle-Pensec V, Gottenberg JE, Jousse-Joulin S, et al. Which and how many patients should be included in randomized controlled trials to demonstrate the efficacy of biologics in primary Sjögren’s syndrome? PLoS One. 2015;10(9):e0133907. DOI:10.1371/journal.pone.0133907
39. Cornec D, Costa S, Devauchelle-Pensec V, et al. Blood and salivary BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren’s syndrome. J Autoimmun. 2016;67:102–110. DOI:10.1016/j.jaut.2015.11.002
40. Delli K, Haacke EA, Kroese FG, et al. Towards personalized treatment in primary Sjögren’s syndrome:baseline parotid histopathology predics responsiveness to rituximab treatment. Ann Rheum Dis. 2016;0:1-6. [Epub ahead of print].
41. Cornec D, Costa S, Devauchelle-Pensec V, et al. Do high numbers of salivary gland-infiltrating B cells predict better or worse outcomes after rituximab in patients with primary Sjögren’s syndrome? Ann Rheum Dis. 2016;75:e33. DOI:10.1136/annrheumdis-2016-209300
42. Delli K, Haacke EA, Kroese FGM, et al. In primary Sjögren’s syndrome high absolute numbers and proportions of B cells in parotid glands predict responsiveness to rituximab as defineb by ESSDAI, but not by SSRI. Ann Rheum Dis. 2016;75:e34. DOI:10.1136/annrheumdis-2016-209317
43. Hillen MR, Barone F, Radstake TRDJ, et al. Towards standardization of histopathologica assessments of germinal centers and lymphoid structures in primary Sjögren’s syndrome. Ann Rheum Dis. 2016;0:1.
44. Quartuccio L, Fabris M, Salvin S, et al. Controversies on rituximab therapy in Sjogren syndrome-associated lymphoproliferation. Int J Rheumatol. 2009;2009:424935. DOI:10.1155/2009/424935
45. Pollard RP, Pijpe J, Bootsma H, et al. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjögren’s syndrome:a retrospective clinical study. J Rheumatol. 2011;38(10):2198–2208. DOI:10.3899/jrheum.110077
46. Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanized anti-CD22 antibody) in primary Sjogren’s syndrome:an open-label phase I/II study. Arthritis Res Ther. 2006;8(4):R129. DOI:10.1186/ar2087
47. Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjogren’s syndrome:results of BELISS open-label phase II study. Ann Rheum Dis. 2015;74(3):526–531. DOI:10.1136/annrheumdis-2013-203991
48. De Vita S, Quartuccio L, Seror R, et al. Efficacy and safety of belimumab given for 12 months in primary Sjogren’s syndrome:the BELISS open-label phase II study. Reumatology (Oxford). 2015;54(12):2249–2256.
49. De Vita S, Quartuccio L, Salvin S, et al. Sequential therapy with belimumab followed by rituximab in Sjogren’s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF:evidence for long-term efficacy. Clin Exp Rheumatol. 2014;32(4):490–494.
50. Cogollo E, Silva MA, Isenberg D. Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther. 2015;9:1331–1339. DOI:10.2147/DDDT.S71276
51. Genovese MC, Lee E, Satterwhite J, et al. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2013;72:1453–1480. DOI:10.1136/annrheumdis-2012-202864
52. Stohl W, Merrill JT, Looney J, et al. Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623):results from randomized, double-blind phase1a and phase 1b trials. Arthritis Res Ther. 2015;17(1):215. DOI:10.1186/s13075-015-0741-z
53. Vugmeyster Y, Seshasayee D, Chang W, et al. A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am J Pathil. 2006;168(2):476–489. DOI:10.2353/ajpath.2006.050600
54. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family:back to the future. Immunity. 2013;39(6):1003–1018. DOI:10.1016/j.immuni.2013.11.010
55. Dubost JJ, Perrier S, Afane M, et al. IL-1 receptor antagonist in saliva; characterization in normal saliva and reduced concentration in Sjögren’s Syndrome (SS). Clin Exp Immunol. 1996;106(2):237–242.
56. Solomon A, Dursun D, Liu Z, et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry eye disease. Invest Ophtalmol Vis Sci. 2001;42(10):2283–2292.
57. Lopalco G, Cantarini L, Vitale A, et al. Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders:premises, perils, and perspectives. Mediators Inflamm. 2015;2015:194864. DOI:10.1155/2015/125380
58. Harboe E, Tjensvoll AB, Vefring HK, et al. Fatigue in primary Sjögren’s syndrome —a link to sickness behavior in animals? Brain Behav Immun. 2009;23(8):1104–1108. DOI:10.1016/j.bbi.2009.06.151
59. Norheim KB, Harboe E, Göransson LG, et al. Interleukin-1 inhibition and fatigue in primary Sjögren’s syndrome —a double blind, randomized clinical trial. Plos One. 2012;7(1):e30123. DOI:10.1371/journal.pone.0030123
60. Dubois EA, Rissmann R, Cohen AF. Rilonacept and canakinumab. Br J Clin Pharmacol. 2011;71(5):639–641. DOI:10.1111/j.1365-2125.2011.03958.x
61. Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune disease. N Eng J Med. 1996;335(18):1369–1377. DOI:10.1056/NEJM199610313351807
62. Chen L, Flies DB. Molecular mechanism of T-cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–242. DOI:10.1038/nri3405
63. Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs:a one-year randomized, placebo-controlled study. Arthritis Rheum. 2006;54(9):2807–2816. DOI:10.1002/art.22070
64. Oxholm P, Daniels TE, Bendtzen K. Cytokine expression in labial salivary glands from patients with primary Sjogren’s syndrome. Autoimmunity. 1992;12:185–191.
65. Matsumura R, Umemiya K, Goto T, et al. Glandular and extraglandular expression of costimulatory molecules in patients with Sjogren’s syndrome. Ann Rheum Dis. 2001;60:473–482.
66. Adler S, Korner M, Forger F, et al. Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjogren syndrome:a pilot study. Arthritis Care Res (Hoboken). 2013;65:1862–1868. DOI:10.1002/acr.22052• This research article discusses the role of Abatacept in the treatment of Sjögren syndrome with primary end point in clinical, histological, and laboratory improvement and patients with longstanding disease
67. Meiners PM, Vissink A, Kroese FG, et al. Abatacept treatment reduces disease activity in early primary Sjogren’s syndrome (open-label proof of concept ASAP study). Ann Rheum Dis. 2014;73(7):1393–1396. DOI:10.1136/annrheumdis-2013-204653.• This research article discusses about the role of Abatacept in the treatment of Sjögren syndrome with primary end point in ESSDAI and ESSPRI and patients with early onset of pSS
68. Papp KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res. 2006;298:7–15. DOI:10.1007/s00403-006-0660-6
69. Tran D, Bebris L, Shevach E, et al. Efalizumab down-regulates CD25 expression of FOXP3+ regulatory T cells and exacerbates the autoimmunity in primary Sjogren’s syndrome. J Immunol. 2010;184(suppl 1):96.4. DOI:10.4049/jimmunol.0902016
70. Molloy ES, Calabrese LH. Therapy:targeted but not trouble-free:efalizumab and PML. Nat Rev Rheumatol. 2009;5(8):418–419. DOI:10.1038/nrrheum.2009.142
71. Aroson R, Gottlieb PA, Christiansen JS, et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study:results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care. 2014;37(10):2746–2754. DOI:10.2337/dc13-0327
72. Youinou P, Pers JO. Disturbance of cytokine networks in Sjogren’s syndrome. Arthr Res Ther. 2011;13(4):227. DOI:10.1186/ar3348
73. Grisius MM, Bermudez DK, Fox PC. Salivary and serum interleukin 6 in primary Sjogren’s syndrome. J Rheumatol. 1997;24(6):1089–1091.
74. Yoon KC, Jeong IY, Park YG, et al. Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. Cornea. 2007;26(4):431–437. DOI:10.1097/ICO.0b013e31803dcda2
75. Hulkkonen J, Pertovaara M, Antonen J, et al. Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjogren’s syndrome and correlate with the clinical manifestation of the disease. Rheumatology (Oxford). 2001;40(6):656–661.
76. Oldfield V, Dhillon S, Plosker GL. Tocilizumab:a review of its use in the management of rheumatoid arthritis. Drugs. 2009;69(5):609–632. DOI:10.2165/00003495-200969050-00007
77. Justet A, Ottaviani S, Dieudé P, et al. Tocilizumab for refractory organising pneumonia associated with Sjogren disease. BMJ Case Rep. 2015;2015. doi:10.1136/bcr-2014-209076
78. Komai T, Shoda H, Yamaguchi K, et al. Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab:a case report. Mod Rheumatol. 2016;26(2):294–296. DOI:10.3109/14397595.2013.861333
79. Efficacy of Tocilizumab in primary Sjögren’s syndrome. [Updated 2016 Aug]. Available from:http://www.trialdetails.com/detail/NCT01782235/Efficacy-of-Tocilizumab-in-Primary-Sj%C3%B6grens-Syndrome
80. Alunno A, Carubbi F, Bartoloni E, et al. Unmasking the pathogenic role of IL-17 axis in primary Sjögren’s syndrome:a new era for therapeutic targeting? Autoimmunity Rev. 2014;13:1167–1173. DOI:10.1016/j.autrev.2014.08.022•• This review summarizes the role of IL-17 pathway in pathogenesis of primary Sjögren syndrome.
81. Blaho VA, Buczynski MW, Dennis EA, et al. Cyclooxygenase-1 orchestrates germinal center formation and antibody class-switch via regulation of IL-17. I Immunol. 2009;183(9):5644–5653. DOI:10.4049/jimmunol.0901499
82. Ferretti E, Di Carlo E, Ognio E, et al. Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma. Oncoimmunology. 2015;4(10):e1030560. DOI:10.1080/2162402X.2015.1008371
83. Lin X, Rui K, Deng L, et al. Th17 cells play a critical role in the development of experimental Sjögren’s syndrome. Ann Rheum Dis. 2014;74(6):1302–1310. DOI:10.1136/annrheumdis-2013-204584
84. Ciccia F, Guggino G, Rizzo A, et al. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren’s syndrome. Rheumatology (Oxford). 2014;53(7):1313–1320. DOI:10.1093/rheumatology/keu004
85. Alunno A, Bistoni O, Caterbi S, et al. Serum interleukin-17 in primary Sjögren’s syndrome:association with disease duration and parotid gland swelling. Clin Exp Rheumatol. 2015;33(1):129.
86. Mieliauskaite D, Dumalakiene I, Rugiene R, et al. Expression of IL-17, IL-23 and their receptors in minor salivary glands of patients with primary Sjögren’s syndrome. Clin Dev Immunol. 2012;2012:187258. DOI:10.1155/2012/187258
87. Alunno A, Carubbi F, Bistoni O, et al. CD4-CD8- T cells in primary Sjögren’s syndrome:association with the extend of glandular involvement. J Autoimmun. 2014;51:38–43. DOI:10.1016/j.jaut.2014.01.030
88. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing Brodalumab with Ustekinumab in psoriasis. N Engl J Med. 2015;373:1318–1328. DOI:10.1056/NEJMoa1503824
89. Leonardi C, Matheson R, Zachariae C, et al. Anti-Interleukin-17 monoclonal antibody Ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190–1199. DOI:10.1056/NEJMoa1109997
90. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371:326–338. DOI:10.1056/NEJMoa1314258
91. Kalunian KC, Merrill JT, Maciuca R, et al. A phase II study of the efficacy and safety of Rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75(1):196–202. DOI:10.1136/annrheumdis-2014-206090
92. Maria NI, Vogelsang P, Versnel MA. The clinical relevance of animal models in Sjögren’s syndrome:the interferon signature from mouse to man. Arthritis Res Ther. 2016;17:172. DOI:10.1186/s13075-015-0678-2
93. Voller J, Tluk S, Schmitz C, et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med. 2005;202(11):1575–1585. DOI:10.1084/jem.20051696
94. Lau CM, Broughton C, Tabor AS, et al. RNA-associated autoantigen activate B cells by combined B cell antigen receptor/Toll-like receptor 7. J Exp Med. 2005;202(9):1171–1177. DOI:10.1084/jem.20050630
95. Pawar RD, Ramanjaneyulu A, Kulkarni OP, et al. Inhibition of Toll-like Receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol. 2007;18:1721–1731. DOI:10.1681/ASN.2006101162
96. Barrat FJ, Meeker T, Chan JH, et al. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol. 2007;37:3582–3586. DOI:10.1002/eji.200737815
97. Cummins MJ, Papas A, Kammer GM, et al. Treatment of primary Sjogren’s syndrome with low-dose human interferon alfa administered by the oromucosal route:combined phase III results. Arthritis Rheum. 2003;49(4):585–593. DOI:10.1002/art.11199
98. Youn SW, Tsai TF, Theng C, et al. The MARCOPOLO study of Ustekinumab utilization and efficacy in a real-world settin:treatment of patients with plaque psoriasis in Asia-Pacific countries. Ann Dermatol. 2016;28(2):222–231. DOI:10.5021/ad.2016.28.2.222
99. Panaccione R, Sandborn WJ, Gordon GL, et al. Briakinumab for treatment of Crohn’s disease:results of a randomized trial. Inflamm Bowel Dis. 2015;21(6):1329–1340. DOI:10.1097/MIB.0000000000000366
100. Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of Guselkumab versus Adalimumab for plaque psoriasis. N Engl J Med. 2015;373:136–144. DOI:10.1056/NEJMoa1501646
101. Vosters JL, Landek-Salgado MA, Yin H, et al. IL-12 induces salivary gland dysfunction, providing a new mouse model of Sjogren’s syndrome. Arthritis Rheum. 2009;60(12):3633–3641. DOI:10.1002/art.24980
102. Nquyen CQ, Hu MH, Li Y, et al. Salivary gland tissue expression of interleukin-23 and interleukin-12 in Sjogren’s syndrome:findings in humans and mice. Arthritis Rheum. 2008;58(3):734–743. DOI:10.1002/art.23214
103. Bombardieri M, Pitzalis C. Ectopic lymphoid neogenesis and lymphoid chemokines in Sjogren’s syndrome:at the interplay between chronic inflammation, autoimmunity and lymphomagenesis. Curr Pharm Biotechnol. 2012;13(10):1989–1996.
104. Nocturne G, Seror R, Fogel O, et al. CXCL13 and CCL11 serum levels and lymphoma and disease activity in primary Sjögren’s syndrome. Arthritis Rheumatol. 2015;67(12):3226–3233. DOI:10.1002/art.39315
105. Gottemberg JE, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome:the JOQUER randomized clinical trial. Jama. 2014;312(3):249–258. DOI:10.1001/jama.2014.7682
106. Safety, pharmacokinetics and preliminary efficacy study of CFZ533 in patients with primary Sjögren’s Syndrome. [Updated 2016 Mar]. Available from:https://clinicaltrials.gov/ct2/show/NCT02291029?term=Sjogren%27s+syndrome&rank=2
107. Safety, pharmacokinetics, and preliminary efficacy study of CDZ137 in patiens with Primary Sjögren’s Syndrome. [Updated 2016 May]. Available from:https://clinicaltrials.gov/ct2/show/NCT02775916?term=Sjogren%27s+syndrome&rank=8
108. UCB proof of concept study in patients with primary Sjögren’s syndrome. [Updated 2015 Nov]. Available from:https://clinicaltrials.gov/ct2/show/NCT02610543?term=UCB5857+AND+Sjogren&rank=1
109. A phase 2a, randomized, placebo controlled, study to evaluate the safety and efficacy of AMG557/MEDI5872 in primary Sjögren’s syndrome. [Updated 2016 Mar]. Available from:https://clinicaltrials.gov/ct2/show/NCT02334306?term=Sjogren%27s+syndrome&rank=13
110. A study to assess the efficacy of RO5459072 in participants with primary Sjögren’s syndrome. [Updated 2016 Aug]. Available from:https://clinicaltrials.gov/ct2/show/NCT02701985?term=sjogren%27s+syndrome&rank=12
111. A safety and efficacy study of 552-02 in subjects with dry mouth associated with Sjögren’s syndrome. [Updated 2014 Jul]. Available from:https://clinicaltrials.gov/ct2/show/NCT00852839?term=sjogren%27s+syndrome&rank=4
112. A phase II study with low–dose recombinant human IL-2 for the treatment of primary Sjögren’s syndrome. [Updated 2015 Jun]. https://clinicaltrials.gov/ct2/show/NCT02464319?term=sjogren%27s+syndrome&rank=27
113. Study of NGX267 oral capsules in patients with xerostomia associated with Sjögren’s syndrome. [Updated 2009 Jan]. Available from:https://clinicaltrials.gov/ct2/show/NCT00637793?term=sjogren%27s+syndrome&rank=40
114. Safety and efficacy study of subcutaneous Belimumab and intravenous Rituximab co-administration in subjects with primary Sjögren’s syndrome. [Updated 2016 Aug]. Available from:https://clinicaltrials.gov/ct2/show/record/NCT02631538?term=sjogren+syndrome&rank=11
115. Efficacy and safety of abatacept in patients with primary Sjögren’s syndrome (ASAPIII). [Updated 2015 Nov]. Available from:https://clinicaltrials.gov/ct2/show/NCT02067910
116. PD of VAY736 in patients with primary Sjögren’s Syndrome (CVAY736X2201). [Updated 2016 Feb]. Available from:https://clinicaltrials.gov/ct2/show/NCT02149420?term=Sjogren%27s+syndrome&rank=9
117. A study of LY3090106 in participants with Sjögren’s Syndrome (SS). [Updated 2016 Aug]. Available from:https://clinicaltrials.gov/ct2/show/NCT02614716?term=Sjogren%27s+syndrome&rank=46
118. Brito Zeron P, Ramon-Casals M, Bove A, et al. Predicting adverse outcomes in primary Sjögren syndrome:identification of prognostic factors. Rheumatology (Oxford). 2007;46(8):1359–1362. DOI:10.1093/rheumatology/kem079
119. Nocturne G, Virone A, Wan-Fai NG, et al. Rheumatoid Factor and disease activity are independent predictors of lymphoma in primary Sjögren’s syndrome. Arthritis Reumatol. 2016;68(4):977–985. DOI:10.1002/art.39518
120. Baimpa E, Dahabreh H, Voulgarelis M, et al. Hematologic manifestation and predictors of lymphoma development in primary Sjögren syndrome:clinical and pathophysiologic aspects. Medicine (Baltimore). 2009;88(5):284–293. DOI:10.1097/MD.0b013e3181b76ab5
121. Chung JK, Kim MK, Wee WR. Prognostic factors fot the clinical severity of keratoconjunctivitis sicca in patients with Sjögren syndrome. Br J Ophthalmol. 2012;96(2):240–245. DOI:10.1136/bjo.2011.202812
122. Bergum B, Koro C, Delaleu N, et al. Antibodies against carbamylated proteins are present in primary Sjögren syndrome and are associated with disease severity. Ann Rheum Dis. 2016;75(8):1494–1500. DOI:10.1136/annrheumdis-2015-207751
123. Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren’s syndrome disease activity index:development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis. 2010;69(6):1103–1109. DOI:10.1136/ard.2009.110619
124. Seror R, Ravaud P, Mariette X, et al. EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI):development of a consensus patient index for primary sjogren’s syndrome. Ann Rheum Dis. 2011;70(6):968–972. DOI:10.1136/ard.2010.143743
125. Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjogren’s syndrome with EULAR primary Sjogren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis. 2016;75(2):382–389. DOI:10.1136/annrheumdis-2014-206008